How to Sell Your Med Spa: Valuation, Buyers, and Deal Structure

Most med spa owners sell exactly once in their life, and they negotiate against buyers who do this every week. Brokers and bankers guard the process because information is their product. I work with med spa owners every day on the marketing side, and I have watched enough exits go sideways to know the pattern: the owners who walk away happy are the ones who understood valuation, buyer types, and deal structure before the first LOI arrived. This guide is the full map — when to sell, what you are worth, who buys, how deals are structured, why they die in diligence, and what to fix in the 12–24 months before you go to market.

When to sell: the market is unusually kind to sellers right now

Two forces are working in your favor. First, the industry keeps growing: the American Med Spa Association (AmSpa) puts the US medical aesthetics industry above $17 billion in annual revenue, with the number of med spas climbing from 8,899 in 2022 to roughly 10,488 in 2023 and a projected 11,553 by 2025. Second, the market is extremely fragmented — roughly 81% of operators run a single location — and private-equity-backed platforms are consolidating it. AmSpa’s own analysis notes that only about 3% of med spas are currently owned by PE firms or PE-backed organizations, which means the roll-up buyers still have years of shopping ahead of them.

The big deals confirm the appetite. Freeman Spogli took a majority position in VIO Med Spa in September 2024, Advanced MedAesthetic Partners (backed by Leon Capital) acquired Ever/Body in December 2025, and Reuters reported that LaserAway engaged Harris Williams in Q2 2026 for a sale process targeting more than $2 billion. When platforms trade at those prices, they need tuck-in acquisitions — clinics like yours — to justify the math.

Market timing matters less than personal readiness, though. In my experience the honest signals that it is time are:

• You have stopped reinvesting — no new devices, no new rooms, no second location — because your heart is not in the next five years.
• Your revenue has plateaued and you know the fix requires energy you do not have.
• You are the top producer and you resent it. Owner-injector burnout is the most common exit trigger I see.
• You have received unsolicited buyer outreach. That is not a reason to sell, but it is a reason to get valuation-ready, because Aesthetic Brokers estimates over 60% of med spa owners engage PE buyers without representation — often by simply answering a “friendly” first call and not realizing the negotiation has already started.

What you’re worth: multiples and the add-back exercise

Med spas are priced on adjusted EBITDA — your true owner earnings after add-backs — multiplied by a market multiple. Per 2025–2026 data from Scope Research and CT Acquisitions’ med spa M&A multiples report, the ranges look like this:

Two adjustments move your number more than anything else. The first is add-backs: your salary above market rate for your clinical role, personal vehicle and travel run through the business, one-time legal or build-out costs, family members on payroll who do not work in the clinic. Documenting these properly can add 20–40% (est.) to your stated EBITDA. The second is recurring revenue: Scope Research’s 2025 analysis found a practice earning 30–40% of revenue from memberships commands 0.5x–1.0x more than an otherwise identical non-membership peer. If you want to know what your membership base is actually worth in enterprise value, run it through my membership MRR calculator.

For a first-pass number on your own clinic, use my free med spa valuation calculator, and read the companion med spa valuation multiples guide for the full breakdown of what pushes a clinic to the top or bottom of its range.

The buyer landscape: who actually buys med spas

PE-backed platforms and MSOs

These are the roll-ups: management services organizations funded by private equity, acquiring clinics to build regional or national brands. They pay the highest multiples for clinics that fit their model — clean books, multiple providers, memberships, $750K+ EBITDA (est. threshold for most platforms). The trade-off: they almost never pay all cash. Expect rollover equity, earnouts, and a multi-year employment agreement. They also demand institutional-grade diligence, which punishes messy financials.

Strategic buyers

Other med spas, dermatology groups, and plastic surgery practices expanding their footprint. They typically pay mid-range multiples but with simpler structures and more cash at close, because they already understand the operations and need less hand-holding. If your clinic sits in a market a growing local competitor wants, a strategic buyer can be the cleanest exit available.

Individual buyers

A nurse practitioner, physician, or first-time entrepreneur buying a single clinic, usually with SBA financing. They pay the lowest multiples (often 2.5x–4x SDE, est.), move slowest because of lender diligence, and are the most sensitive to owner-dependence — if the business is you, they cannot get the loan. But for smaller clinics under roughly $500K EBITDA, an individual buyer is often the only realistic buyer pool.

Deal structures decoded

Asset sale vs. stock sale

Most med spa deals under $5M are asset sales: the buyer purchases equipment, patient lists, brand, and contracts, and leaves your legal entity (and its liabilities) behind. Buyers prefer this for liability and tax reasons; sellers usually pay somewhat more tax. Stock/equity sales are more common in larger platform deals and are often cleaner when licenses, payer relationships, or leases are hard to reassign.

Cash, rollover equity, and earnouts

Per medspabusinessbroker.com’s 2025 market summary, most MSO transactions are structured around 60% cash at close plus 40% rollover equity, ranging up to 80/20, with holdbacks and earnouts standard — particularly earnouts tied to provider retention. The rules I give every owner:

1. Only the cash at close is real. Value rollover equity and earnouts at a steep discount when comparing offers.
2. Rollover equity is a second bet, not a bonus. The “second bite of the apple” pitch is genuine — sellers in successful platforms have done very well — but you must understand the equity class, dilution risk, preferred returns ahead of you, and when (if ever) you can get liquid.
3. Never accept an earnout tied to metrics the buyer controls. If they set the marketing budget, staffing, and pricing after close, they control whether you hit your targets.

The employment tie-in

If you are the owner-injector, nearly every buyer will require you to stay on for 2–3 years post-close, usually with a salary, production bonus, and a non-compete. This is not negotiable in most platform deals — your patient relationships are a large part of what they are buying. Plan your exit date accordingly: if you want to be fully out by 2029, you need to be signing in 2026–2027.

The license problem: why deals die in diligence

This is the med spa-specific landmine. Most states have corporate practice of medicine (CPOM) rules restricting who can own a clinical practice, which is why buyers use MSO structures that separate the medical entity (physician-owned) from the management company (investor-owned). Deal advisors at SovDoc and CT Acquisitions consistently report that messy books and legal surprises in diligence are the number one deal killers, and clinical oversight structure is at the top of the legal list. Sophisticated buyers verify medical director arrangements early, and a weak or informal one can delay or kill a closing.

Before you go to market, pressure-test three things: Is your MSO/medical-entity structure actually compliant in your state, or is it a handshake? Does your medical director agreement survive a change of ownership, and will that physician stay through transition? Are your delegation protocols, good-faith exams, and supervision documentation in order? The same discipline applies to your marketing claims — buyers increasingly audit advertising for regulatory exposure, which I cover in my med spa advertising compliance guide. Sell-side diligence — auditing yourself before buyers do — consistently produces higher multiples and smoother closes.

The 12–24 month prep checklist

• Clean the books. Move to accrual accounting, separate personal expenses, document every add-back with receipts. Consider a reviewed financial statement or a light quality-of-earnings report.
• Reduce owner-dependence. Shift your injection volume to associate providers over 12–18 months. A clinic where the owner produces 70% of revenue is a job, not an asset.
• Lock provider contracts. Buyers pay for a team that stays. Employment agreements with reasonable non-solicits for your injectors materially de-risk the deal.
• Build the membership base. Recurring revenue is the single highest-ROI valuation lever — see the multiple premium above.
• Fix the growth story. Buyers pay for a clinic that is growing into the deal, not out of it. A working patient-acquisition engine — strong local search visibility, paid campaigns that track to booked appointments, a full med spa marketing system — directly supports a higher multiple. And plug the revenue leaks buyers will find in diligence: run my missed-call calculator and no-show cost calculator to see what unanswered phones and empty chairs cost you annually, because a buyer’s analyst absolutely will.
• Fix the legal stack. CPOM structure, medical director agreement, lease assignability, device titles and lien releases.

Broker vs. banker vs. direct: what representation costs

Per Morgan & Westfield’s fee guide and CT Acquisitions’ 2026 broker fee breakdown: business brokers on sub-$1M deals charge roughly 8–12% of the sale price (the smallest deals sometimes 12–15%), and sub-$2M deals blend out around 6–10% — so budgeting est. 8–12% under $2M is realistic. M&A advisors on $2M–$50M deals average 3–6%, often on a Lehman-style tiered scale (e.g., 10% of the first $1M, 8% of the second, and so on) plus a $2,500–$10,000 monthly retainer credited against the success fee. Investment banks above ~$50M charge 1–3% with large minimum fees.

Is representation worth it? Aesthetic Brokers reports that sellers with experienced M&A advisors achieve on average 23% higher EBITDA multiples — more than covering the fee on most deals. My practical rule: under ~$500K EBITDA with a likely individual buyer, a good broker earns their fee by running a confidential process and keeping the deal alive. Between $750K and $2M+ EBITDA with platform interest, a healthcare-focused M&A advisor who can run a competitive process among multiple MSOs is usually the single best investment in the entire exit. Going direct only makes sense when a specific strategic buyer approached you, you have already validated the price against market data, and you hire a strong healthcare M&A attorney to paper it.

Timeline: what 6–12 months actually looks like

1. Months 1–2: Valuation, financial packaging, confidential information memorandum.
2. Months 2–4: Buyer outreach, NDAs, management calls, indications of interest.
3. Months 4–6: LOI negotiation and signing. Remember: your negotiating position peaks right before you sign — once exclusivity starts, it drops sharply, so get structure, earnout terms, and employment terms into the LOI.
4. Months 6–9: Due diligence — financial, legal, clinical, regulatory. This is where unprepared deals die or get repriced.
5. Months 9–12: Definitive agreements, medical director and license transitions, closing.

Well-prepared clinics with clean books close near the front of that range; owners who start diligence prep after the LOI routinely blow past it.

Want a second set of eyes on this for your clinic? Book a free strategy call or call/text me at +91 97297 12388.

Frequently asked questions

How much can I sell my med spa for?

Most single-location med spas sell for 3x–6x adjusted EBITDA, per 2025–2026 market data from Scope Research and CT Acquisitions. A clinic producing $500K in adjusted EBITDA typically trades between $1.5M and $3M, with recurring membership revenue, multiple providers, and clean books pushing you toward the top of the range. Use my valuation calculator for a first estimate.

How long does it take to sell a med spa?

Plan on 6–12 months from engaging an advisor to closing, plus 12–24 months of preparation before that if you want top-of-range pricing. Diligence is the longest and most fragile phase — clean financials and a compliant CPOM structure are what keep you on the shorter end.

Do I have to keep working after I sell?

If you are the owner-injector, almost certainly yes. Most platform and MSO buyers require a 2–3 year employment agreement post-close, because your patient relationships are a core part of the asset. If you want a clean walk-away, expect a lower price and a smaller buyer pool.

What is rollover equity and should I accept it?

Rollover equity means reinvesting part of your sale proceeds into the buyer’s platform — most 2025 MSO deals ran 60–80% cash at close with 20–40% rolled, per medspabusinessbroker.com. It can produce a valuable “second bite” when the platform sells, but it is not guaranteed money: scrutinize the equity class, dilution, preferred returns, and liquidity timing before agreeing.

Why do med spa sales fall apart in due diligence?

The two most common killers, per deal advisors at SovDoc and CT Acquisitions, are messy financials and legal surprises — especially non-compliant corporate practice of medicine structures and weak medical director arrangements. Self-auditing both before going to market is the cheapest insurance you can buy.

Do I need a broker to sell my med spa?

Not legally, but the data favors representation: Aesthetic Brokers reports sellers with experienced M&A advisors achieve about 23% higher EBITDA multiples on average. Budget est. 8–12% in fees on deals under $2M and 3–6% on larger deals. Going direct is only sensible with a validated price, a specific inbound buyer, and a strong healthcare M&A attorney.

What makes a med spa more valuable to buyers?

Recurring membership revenue (worth an extra 0.5x–1.0x on the multiple, per Scope Research), provider teams under contract, low owner-dependence, documented add-backs, a compliant legal structure, and a marketing engine that generates predictable new-patient flow rather than relying on the owner’s personal reputation.